Skip to main content

1 Result(s)

within Yarong Li Remove this filter Cancer Research Remove this filter

and
Your search also matched 1 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

High Wilms’ tumor 1 associating protein expression predicts poor prognosis in acute myeloid leukemia and regulates m6A methylation of MYC mRNA

Include preview-only content

  1. Article

    Open Access

    Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

    HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report th...

    Yan Qin, Yong** Song, Dong Wang, Ou Bai, Jifeng Feng, **uhua Sun, Lihua Qiu… in BMC Cancer (2024)

    Download PDF (3171 KB) View Article